SGSigurjon Axel Gudjonsson

Sigurjon Axel Gudjonsson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sigurjon Axel Gudjonsson has a total of 782 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sequence variants affecting voice pitch in humans

    by Rosa S. Gisladottir, Agnar Helgason, Bjarni V. Halldorsson, Hannes Helgason, Michal Borsky, Yu-Ren Chien, Jon Gudnason, Sigurjon A. Gudjonsson, Scott Moisik, Dan Dediu, et al.

    The genetic basis of the human vocal system is largely unknown, as are the sequence variants that give rise to individual differences in voice and speech. Here, we couple data on diversity in the sequence of the genome with voice and vowel acoustics in speech recordings from 12,901 Icelanders. We show how voice pitch and vowel acoustics vary across the life span and correlate with anthropometric, physiological, and cognitive traits. We found that voice pitch and vowel acoustics have a heritable component and discovered correlated common variants in ABCC9 that associate with voice pitch. The ABCC9 variants also associate with adrenal gene expression and cardiovascular traits. By showing that voice and vowel acoustics are influenced by genetics, we have taken important steps toward understanding the genetics and evolution of the human vocal system.


  • Open Access

    Large-scale comparison of immunoassay- and aptamer-based plasma proteomics through genetics and disease

    by Grimur Hjorleifsson Eldjarn, Egil Ferkingstad, Sigrun H. Lund, Hannes Helgason, Olafur Th. Magnusson, Thorunn A. Olafsdottir, Bjarni V. Halldorsson, Pall I. Olason, Florian Zink, Sigurjon A. Gudjonsson, et al.

    High-throughput proteomics platforms measuring thousands of proteins in blood combined with genomic information have the power to bridge the gap between the genome and diseases and in that capture some of the environmental contributions to their risk and pathogenesis. Although such methods have already demonstrated their utility1–3, the validation of their actual protein targets is lacking. Here we present a large-scale analysis of levels of proteins in plasma and protein quantitative trait loci (pQTLs) detected using the Olink Explore 1536 (1,459 immunoassays) in 47,151 European participants from the UK Biobank with 57.7 million imputed sequence variants. We compared the results with those of a large-scale SomaScan v4 study2 (35,559 participants and 4,907 aptamer-based assays) in order to assess and compare the qualities of these two platforms. The correlation between levels of proteins targeted by the two platforms is modest (median Spearman correlation 0.46). The vast majority of assays on the Olink Explore platform had cis pQTLs, evidence that they correctly target their intended proteins (84%), while the assays on the SomaScan v4 platform were half as likely to have cis pQTLs (38%). We also highlight novel pQTLs discovered using the Olink Explore platform, not captured by SomaScan v4, and describe their colocalization with disease-associated sequence variants as well as associations between protein levels and diseases. Our results further underscore the value of proteomics data and highlight the major differences in quality between the two most commonly used high-throughput proteomics platforms.


  • Open Access

    Long read sequencing of 3,622 Icelanders provides insight into the role of structural variants in human diseases and other traits

    by Doruk Beyter, Helga Ingimundardottir, Asmundur Oddsson, Hannes P. Eggertsson, Eythor Bjornsson, Hakon Jonsson, Bjarni A. Atlason, Snaedis Kristmundsdottir, Svenja Mehringer, Marteinn T. Hardarson, et al.

    Long-read sequencing (LRS) promises to improve characterization of structural variants (SVs), a major source of genetic diversity. We generated LRS data on 3,622 Icelanders using Oxford Nanopore Technologies, and identified a median of 22,636 SVs per individual (a median of 13,353 insertions and 9,474 deletions), spanning a median of 10 Mb per haploid genome. We discovered a set of 133,886 reliably genotyped SV alleles and imputed them into 166,281 individuals to explore their effects on diseases and other traits. We discovered an association with a rare (AF = 0.037%) deletion of the first exon of PCSK9 . Carriers of this deletion have 0.93 mmol/L (1.31 SD) lower LDL cholesterol levels than the population average (p-value = 7.0·10 −20 ). We also discovered an association with a multi-allelic SV inside a large repeat region, contained within single long reads, in an exon of ACAN . Within this repeat region we found 11 alleles that differ in the number of a 57 bp-motif repeat, and observed a linear relationship (0.016 SD per motif inserted, p = 6.2·10 −18 ) between the number of repeats carried and height. These results show that SVs can be accurately characterized at population scale using long read sequence data in a genome-wide non-targeted approach and demonstrate how SVs impact phenotypes.


  • Top Cited Papers

    Characterizing mutagenic effects of recombination through a sequence-level genetic map

    by Bjarni V. Halldorsson, Gunnar Palsson, Olafur A. Stefansson, Hakon Jonsson, Marteinn T. Hardarson, Hannes P. Eggertsson, Bjarni Gunnarsson, Asmundur Oddsson, Gisli H. Halldorsson, Florian Zink, et al.

    Human recombination and mutation mapped: Genetic recombination is an essential process in generating genetic diversity. Recombination occurs both through the shuffling of maternal and paternal chromosomes and through mutations generated by resolution of the physical breaks necessary for this process. Halldorsson et al. sequenced the full genomes of parents and offspring to create a map of human recombination and estimate the relationship with de novo mutations. Interestingly, transcribed regions of the genome were less likely to have crossovers, suggesting that there may be selection to reduce changes in genetic sequences via recombination or mutation in these regions. Science , this issue p. eaau1043


  • Open Access

    Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA

    by Julius Gudmundsson, Jon K. Sigurdsson, Lilja Stefansdottir, Bjarni A. Agnarsson, Helgi J. Isaksson, Olafur A. Stefansson, Sigurjon A. Gudjonsson, Daniel F. Gudbjartsson, Gisli Masson, Michael L. Frigge, et al.

    Benign prostatic hyperplasia and associated lower urinary tract symptoms (BPH/LUTS) are common conditions affecting the majority of elderly males. Here we report the results of a genome-wide association study of symptomatic BPH/LUTS in 20,621 patients and 280,541 controls of European ancestry, from Iceland and the UK. We discovered 23 genome-wide significant variants, located at 14 loci. There is little or no overlap between the BPH/LUTS variants and published prostate cancer risk variants. However, 15 of the variants reported here also associate with serum levels of prostate specific antigen (PSA) (at a Bonferroni corrected P < 0.0022). Furthermore, there is a strong genetic correlation, rg = 0.77 (P = 2.6 × 10−11), between PSA and BPH/LUTS, and one standard deviation increase in a polygenic risk score (PRS) for BPH/LUTS increases PSA levels by 12.9% (P = 1.6×10−55). These results shed a light on the genetic background of BPH/LUTS and its substantial influence on PSA levels.


  • Multiple transmissions of de novo mutations in families

    by Hákon Jónsson, Patrick Sulem, Gudny A. Arnadottir, Gunnar Pálsson, Hannes P. Eggertsson, Snaedis Kristmundsdottir, Florian Zink, Birte Kehr, Kristjan E. Hjorleifsson, Brynjar Ö. Jensson, et al.

    De novo mutations (DNMs) cause a large proportion of severe rare diseases of childhood. DNMs that occur early may result in mosaicism of both somatic and germ cells. Such early mutations can cause recurrence of disease. We scanned 1,007 sibling pairs from 251 families and identified 878 DNMs shared by siblings (ssDNMs) at 448 genomic sites. We estimated DNM recurrence probability based on parental mosaicism, sharing of DNMs among siblings, parent-of-origin, mutation type and genomic position. We detected 57.2% of ssDNMs in the parental blood. The recurrence probability of a DNM decreases by 2.27% per year for paternal DNMs and 1.78% per year for maternal DNMs. Maternal ssDNMs are more likely to be T>C mutations than paternal ssDNMs, and less likely to be C>T mutations. Depending on the properties of the DNM, the recurrence probability ranges from 0.011% to 28.5%. We have launched an online calculator to allow estimation of DNM recurrence probability for research purposes.


  • Open Access

    A homozygous loss-of-function mutation leading to CYBC1 deficiency causes chronic granulomatous disease

    by Gudny A. Arnadottir, Gudmundur L. Norddahl, Steinunn Gudmundsdottir, Arna B. Agustsdottir, Snaevar Sigurdsson, Brynjar O. Jensson, Kristbjorg Bjarnadottir, Fannar Theodors, Stefania Benonisdottir, Erna V. Ivarsdottir, et al.

    Mutations in genes encoding subunits of the phagocyte NADPH oxidase complex are recognized to cause chronic granulomatous disease (CGD), a severe primary immunodeficiency. Here we describe how deficiency of CYBC1, a previously uncharacterized protein in humans (C17orf62), leads to reduced expression of NADPH oxidase’s main subunit (gp91phox) and results in CGD. Analyzing two brothers diagnosed with CGD we identify a homozygous loss-of-function mutation, p.Tyr2Ter, in CYBC1. Imputation of p.Tyr2Ter into 155K chip-genotyped Icelanders reveals six additional homozygotes, all with signs of CGD, manifesting as colitis, rare infections, or a severely impaired PMA-induced neutrophil oxidative burst. Homozygosity for p.Tyr2Ter consequently associates with inflammatory bowel disease (IBD) in Iceland (P = 8.3 × 10−8; OR = 67.6), as well as reduced height (P = 3.3 × 10−4; −8.5 cm). Overall, we find that CYBC1 deficiency results in CGD characterized by colitis and a distinct profile of infections indicative of macrophage dysfunction.


  • Insights into imprinting from parent-of-origin phased methylomes and transcriptomes

    by Florian Zink, Droplaug N. Magnusdottir, Olafur T. Magnusson, Nicolas J. Walker, Tiffany J. Morris, Asgeir Sigurdsson, Gisli H. Halldorsson, Sigurjon A. Gudjonsson, Pall Melsted, Helga Ingimundardottir, et al.

    Imprinting is the preferential expression of one parental allele over the other. It is controlled primarily through differential methylation of cytosine at CpG dinucleotides. Here we combine 285 methylomes and 11,617 transcriptomes from peripheral blood samples with parent-of-origin phased haplotypes, to produce a new map of imprinted methylation and gene expression patterns across the human genome. We demonstrate how imprinted methylation is a continuous rather than a binary characteristic. We describe at high resolution the parent-of-origin methylation pattern at the 15q11.2 Prader–Willi/Angelman syndrome locus, with nearly confluent stochastic paternal methylation punctuated by ‘spikes’ of maternal methylation. We find examples of polymorphic imprinted methylation unrelated (at VTRNA2-1 and PARD6G) or related (at CHRNE) to nearby SNP genotypes. We observe RNA isoform-specific imprinted expression patterns suggestive of a methylation-sensitive transcriptional elongation block. Finally, we gain new insights into parent-of-origin-specific effects on phenotypes at the DLK1/MEG3 and GNAS loci.


  • Open Access

    Recurrence of de novo mutations in families

    by Hákon Jónsson, Patrick Sulem, Gudny A. Arnadottir, Gunnar Pálsson, Hannes P. Eggertsson, Snaedis Kristmundsdottir, Florian Zink, Birte Kehr, Kristjan E. Hjorleifsson, Brynjar Orn Jensson, et al.

    De novo mutations (DNMs) cause a large fraction of severe rare diseases of childhood. DNMs that occur in early embryos may result in mosaicism of both somatic and germ cells. Such early mutations may be transmitted to more than one offspring and cause recurrence of serious disease. We scanned 1,007 sibling pairs from 251 families and identified 885 DNMs shared by siblings (ssDNMs) at 451 genomic sites. We estimated the probability of DNM recurrence based on presence in the blood of the parent, sharing by other siblings, parent-of-origin, mutation type, and genomic position. We detected 52.1% of ssDNMs in the parental blood. The probability of a DNM being shared goes down by 2.28% per year for paternal DNMs and 1.82% for maternal DNMs. Shared paternal DNMs are more likely to be T>C mutations than maternal ones, but less likely to be C>T mutations. Depending on DNM properties, the probability of recurrence in a younger sibling ranges from 0.013% to 29.6%. We have launched an online DNM recurrence probability calculator, to use in genetic counselling in cases of rare genetic diseases.


  • Open Access

    Compound heterozygous mutations in UBA5 causing early-onset epileptic encephalopathy in two sisters

    by Gudny A. Arnadottir, Brynjar O. Jensson, Sigurdur E. Marelsson, Gerald Sulem, Asmundur Oddsson, Ragnar P. Kristjansson, Stefania Benonisdottir, Sigurjon A. Gudjonsson, Gisli Masson, Gudmundur A. Thorisson, et al.

    Epileptic encephalopathies are a group of childhood epilepsies that display high phenotypic and genetic heterogeneity. The recent, extensive use of next-generation sequencing has identified a large number of genes in epileptic encephalopathies, including UBA5 in which biallelic mutations were first described as pathogenic in 2016 (Colin E et al., Am J Hum Genet 99(3):695-703, 2016. Muona M et al., Am J Hum Genet 99(3):683-694, 2016). UBA5 encodes an activating enzyme for a post-translational modification mechanism known as ufmylation, and is the first gene from the ufmylation pathway that is linked to disease. We sequenced the genomes of two sisters with early-onset epileptic encephalopathy along with their unaffected parents in an attempt to find a genetic cause for their condition. The sisters, born in 2004 and 2006, presented with infantile spasms at six months of age, which later progressed to recurrent, treatment-resistant seizures. We detected a compound heterozygous genotype in UBA5 in the sisters, a genotype not seen elsewhere in an Icelandic reference set of 30,067 individuals nor in public databases. One of the mutations, c.684G > A, is a paternally inherited exonic splicing mutation, occuring at the last nucleotide of exon 7 of UBA5. The mutation is predicted to disrupt the splice site, resulting in loss-of-function of one allele of UBA5. The second mutation is a maternally inherited missense mutation, p.Ala371Thr, previously reported as pathogenic when in compound heterozygosity with a loss-of-function mutation in UBA5 and is believed to produce a hypomorphic allele. Supportive of this, we have identified three adult Icelanders homozygous for the p.Ala371Thr mutation who show no signs of neurological disease. We describe compound heterozygous mutations in the UBA5 gene in two sisters with early-onset epileptic encephalopathy. To our knowledge, this is the first description of mutations in UBA5 since the initial discovery that pathogenic biallelic variants in the gene cause early-onset epileptic encephalopathy. We further provide confirmatory evidence that p.Ala371Thr is a hypomorphic mutation, by presenting three adult homozygotes who show no signs of neurological disease.